Effect of Ox-LDL on endothelium-dependent response in pig ciliary artery: Prevention by an ET(A) antagonist

Investigative Ophthalmology and Visual Science

Volumn 40, Issue 5, 1999, Pages 1015-1020

  Zhu, Peili ^b   Dettmann, Eike S ^b   Resink, Thérèse J ^b   Lüscher, Thomas F ^b   Flammer, Josef ^b   Haefliger, Ivan O ^a  

^a UNIVERSITY EYE CLINIC   (Switzerland)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

15 HYDROXY 11ALPHA,9ALPHA EPOXYMETHANOPROSTA 5,13 DIENOIC ACID; BRADYKININ; CYCLO(DEXTRO TRYPTOPHYL DEXTRO ASPARTYLPROLYL DEXTRO VALYLLEUCYL); CYCLOHEXIMIDE; ENDOTHELIN 1; ENDOTHELIN A RECEPTOR ANTAGONIST; OXIDIZED LOW DENSITY LIPOPROTEIN; PROTEIN SYNTHESIS INHIBITOR; THROMBOXANE A2;

ANIMAL TISSUE; ARTERY ENDOTHELIUM; ARTICLE; ATHEROSCLEROTIC PLAQUE; CILIARY ARTERY; CONTROLLED STUDY; DRUG EFFECT; EYE BLOOD FLOW; HYPERCHOLESTEROLEMIA; ISOLATED ARTERY; NONHUMAN; PRIORITY JOURNAL; SWINE; VASOCONSTRICTION; VASODILATATION;

15-HYDROXY-11 ALPHA,9 ALPHA-(EPOXYMETHANO)PROSTA-5,13-DIENOIC ACID; ANIMALS; BRADYKININ; CILIARY ARTERIES; CYCLOHEXIMIDE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG COMBINATIONS; ENDOTHELIUM, VASCULAR; HUMANS; ISOMETRIC CONTRACTION; LIPOPROTEINS, LDL; MUSCLE, SMOOTH, VASCULAR; OXIDATION-REDUCTION; PEPTIDES, CYCLIC; PROTEIN SYNTHESIS INHIBITORS; RECEPTORS, ENDOTHELIN; SWINE; VASOCONSTRICTOR AGENTS;

EID: 0032994544     PISSN: 01460404     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Lüscher TF, Tanner FC, Dohi Y. Age, hypertension and hypercholesterolemia alter endothelium-dependent vascular regulation. Pharmacol Taxicol. 1992;70(suppl):S32-S39.
2. Juul K, Nielsen LB, Munkholm K, Stender S, Nordestgaard BG. Oxidation of plasma low-density lipoprotein accelerates its accumulation and degradation in the arterial wall in vivo. Circulation. 1996;94:1698-1704.
3. Henriksen T, Mahoney EM, Steinberg D. Enhanced macrophage degradation of biologically modified low density lipoprotein. Arteriosclerosis. 1983;3:149-159.
4. Yla HS, Palinski W, Rosenfeld ME, et al. Evidence for the presence of oxidatively modified low density lipoprotein in atherosclerotic lesions of rabbit and man. J Clin Invest. 1989;84:1086-1095.
5. Furchgott RF. The discovery of endothdium-dependent relaxation. Circulation. 1993;87(suppl V):V3-V8.
6. Lüscher TF, Boulanger CM, Dohi Y, Yang Z. Endothelium-derived contracting factors. Hypertension. 1992;19:117-130.
7. Noll G, Lüscher TF. Influence of lipoproteins on endothelial function. Thromb Res. 1994;74(suppl 1):S45-S54.
8. Galle J, Bengen J, Schollmeyer P, Wanner C. Oxidized lipoprotein(a) inhibits endothelium-dependent dilation: prevention by high density lipoprotein. Eur J Pharmcol. 1994;265:111-115.
9. Treasure CB, Klein JL, Weintraub WS, et al. Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease. N Engl J Med. 1995;332:481-487.
10. Tanner FC, Tschudi MR, Lüscher TF. Endothelium, lipoproteins and atherosclerotic vascular disease. Vasc Med Rev. 1991;2:121-176.
11. Tanner FC, Noll G, Boulanger CM, Lüscher TF. Oxidized low density lipoproteins inhibit relaxations of porcine coronary arteries. Circulation. 1991;83:2012-2020.
12. Anderson TJ, Meredith IT, Yeung AC, Frei B, Selwyn AP, Ganz P. The effect of cholesterol-lowering and antioxidant therapy on endothelium-dependent coronary vasomotion. N Engl J Med. 1995;332:488-493.
13. Leung WH, Lau CP, Wong CK Beneficial effect of cholesterollowering therapy on coronary endothelium-dependent relaxation in hypercholesterolemic patients. Lancet 1993;341:1496-1500.
14. Boulanger CM, Tanner FC, Bea ML, Hahn AW, Werner A, Lüscher TF. Oxidized low density lipoproteins induce mRNA expression and release of endothelin from human and porcine endothelium. Circ Res. 1992;70:1191-1197.
15. Lerman A, Edwards BS, Hallett JW, Heublein DM, Sandberg SM, Burnett JC. Circulating and tissue endothelin immunoreacting in advanced atherosclerosis. N Engl J Med. 1991;325:997-1001.
16. Prince JH, Diesem CD. Anatomy and Histology of the Eye and Orbit in Domestic Animals. Springfield, IL: Charles C Thomas; 1960:221-230.
17. Haefliger IO, Flammer J, Lüscher TF. Heterogeneity of endothelium-dependent regulation in ophthalmic and ciliary arteries. Invest Ophthalmol Vis Sci. 1993;34:1722-1730.
18. Haefliger IO, Flammer J, Lüscher TF. Nitric oxide and endothelin-1 are important regulators of human ophthalmic artery. Invest Ophthalmol Vis Sci. 1992;33:2340-2343.
19. Meyer P, Flammer J, Lüscher TF. Local action of the renin angiotensin system in the porcine ophthalmic circulation: effects of ACE-inhibitors and angiotensin receptor antagonists. Invest Ophthalmol Vis Sci. 1995;36:555-562.
20. B, receptors mediate contraction to endothelin-1 in human blood vessels [see comments]. Circulation. 1994;89:1203-1208.
21. Orlov S, Resink TJ, Berhardt J, Ferracin F, Buhler FR. Vascular smooth muscle cell calcium fluxes. Regulation by angiotensin II and lipoproteins. Hypertension 1993;21:195-203.
22. Kuzmenko YS, Bochkov N, Philippova MP, Tkachuk VA, Resink TJ. Characterization of an atypical lipoprotein-binding protein in human aortic media membranes by ligand blotting. Biochem J. 1994;303:281-287.
23. Yao K, Tschudi M, Flammer J, Lüscher TF. Endothelium-dependent regulation of vascular tone of the porcine ophthalmic artery. Invest Ophthalmol Vis Sci. 1991;32:1791-1798.
24. +-channels. Invest Ophthalmol Vis Sci. 1997;38:1761-1767.
25. Ruffolo JRR. Endothelin Receptors. From the Gene to the Human. Boca Raton, FL: CRC Press: 1995:1-285.
26. Lüscher TF. Do we need endothelin antagonists? Cardiorasc Res. 1993;27:2089-2093.
27. McMurdo L, Corder R, Thiemermann C, Vane JR. Incomplete inhibition of the pressor effect of endothelin-1 and related peptides in the anaesthetized rat with BQ 123 provides evidence for more than one vasoconstrictor receptor. Br J Pharmacol. 1993; 108:557-561.
28. Simon BC, Cunningham LD, Cohen RA. Oxidized low density lipoproteins cause contraction and inhibit endothelium-dependent relaxation in the pig coronary artery. J Clin Invest. 1990;86:75-79.
29. Murohara T, Kugiyama K, Ohgushi M, Sugiyama S, Ohta Y, Yasue H. LPC in oxidized LDL elicits vasocontraction and inhibits endothelium-dependent relaxation. Am J Physiol. 1994;36:H2441-H2449.
30. Matsuda Y, Hirata K, Inoue N, et al. High density lipoprotein reverses inhibitory effect of oxidized low density lipoprotein on endothelium-dependent arterial relaxation. Circ Res. 1993;72: 1103-1109.
31. Mehta JL, Bryant JJ, Mehta P. Reduction of nitric oxide synthase activity in human neutrophils by oxidized low-density lipoproteins. Reversal of the effect of oxidized low-density lipoproteins by high-density lipoproteins and L-arginine. Biochem Pharmacol. 1995;50:1181-1185.
32. Chin JH, Azhar S, Hoffman BB. Inactivation of endothelial derived relaxing factor by oxidized lipoproteins. J Clin Invest. 1992;89: 10-18.
33. A receptor blockade restores nitric oxide-mediated endothelial function and inhibits atherosclerosis in the aorta of ApoE knockout mice (Abstract). Hospitalis. 1998; 67(suppl):S18.
34. Yla HS, Palinski W, Butler SW, Picard S, et al. Rabbit and human atherosclerotic lesions contain IgG that recognizes epitopes of oxidized LDL. Arterioscler Thromb. 1994;14:32-40.
35. Palinski W, Tangirala RK, Miller E, et al. Increased autoantibody titers against epitopes of oxidized LDL in LDL receptor-deficient mice with increased atherosclerosis. Arterioscler Thromb Vasc Biol. 1995;15:1569-1576.
36. Haller H. Mechanisms of early atherogenesis: the endothelium and cardiovascular risk factor. J Cardiovasc Pharmacol. 1996; 28(suppl 3):S22-S26.
37. Haas A, Walzl M, Jesenik F, et al. Application of HELP in nonarteritic anterior ischemic optic neuropathy: a prospective, randomized, controlled study. Graefes Arch Clin Exp Ophthalmol 1997; 235:14-19.
38. Talks SJ, Chong NH, Gibson JM, Dodson PM. Fibrinogen, cholesterol and smoking as risk factors for non-arteritic anterior ischemic optic neuropathy. Eye. 1995;9:85-88